126 related articles for article (PubMed ID: 38653530)
1. Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS.
Cetin Gedik K; Ortega-Villa AM; Materne G; Rastegar A; Montealegre Sanchez GA; Reinhardt A; Brogan PA; Berkun Y; Murias S; Robles M; Schalm S; de Jesus AA; Goldbach-Mansky R
Ann Rheum Dis; 2024 Apr; ():. PubMed ID: 38653530
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
[TBL] [Abstract][Full Text] [Related]
3. A case of mother and child with CANDLE syndrome: Diagnosis and subsequent treatment with baricitinib.
Guo W; Lozeau D; Tonnesen M; Schuval S; de Jesus A; Miller D; Alehashemi S; Kristal L
Pediatr Dermatol; 2024 Jun; ():. PubMed ID: 38881047
[TBL] [Abstract][Full Text] [Related]
4. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
[TBL] [Abstract][Full Text] [Related]
5. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
[TBL] [Abstract][Full Text] [Related]
6. Identification of eight novel proteasome variants in five unrelated cases of proteasome-associated autoinflammatory syndromes (PRAAS).
Papendorf JJ; Ebstein F; Alehashemi S; Piotto DGP; Kozlova A; Terreri MT; Shcherbina A; Rastegar A; Rodrigues M; Pereira R; Park S; Lin B; Uss K; Möller S; da Silva Pina AF; Sztajnbok F; Torreggiani S; Niemela J; Stoddard J; Rosenzweig SD; Oler AJ; McNinch C; de Guzman MM; Fonseca A; Micheloni N; Fraga MM; Perazzio SF; Goldbach-Mansky R; de Jesus AA; Krüger E
Front Immunol; 2023; 14():1190104. PubMed ID: 37600812
[TBL] [Abstract][Full Text] [Related]
7. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
8. CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature-a rare case with a novel mutation.
Cavalcante MP; Brunelli JB; Miranda CC; Novak GV; Malle L; Aikawa NE; Jesus AA; Silva CA
Eur J Pediatr; 2016 May; 175(5):735-40. PubMed ID: 26567544
[TBL] [Abstract][Full Text] [Related]
9. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.
Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
Ann Rheum Dis; 2022 May; 81(5):601-613. PubMed ID: 35086813
[TBL] [Abstract][Full Text] [Related]
10. Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome.
Boyadzhiev M; Marinov L; Boyadzhiev V; Iotova V; Aksentijevich I; Hambleton S
Pediatr Rheumatol Online J; 2019 May; 17(1):19. PubMed ID: 31046790
[TBL] [Abstract][Full Text] [Related]
11. CANDLE Syndrome As a Paradigm of Proteasome-Related Autoinflammation.
Torrelo A
Front Immunol; 2017; 8():927. PubMed ID: 28848544
[TBL] [Abstract][Full Text] [Related]
12. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS.
Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
Arthritis Rheumatol; 2022 May; 74(5):735-751. PubMed ID: 35315249
[TBL] [Abstract][Full Text] [Related]
13. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.
Brehm A; Liu Y; Sheikh A; Marrero B; Omoyinmi E; Zhou Q; Montealegre G; Biancotto A; Reinhardt A; Almeida de Jesus A; Pelletier M; Tsai WL; Remmers EF; Kardava L; Hill S; Kim H; Lachmann HJ; Megarbane A; Chae JJ; Brady J; Castillo RD; Brown D; Casano AV; Gao L; Chapelle D; Huang Y; Stone D; Chen Y; Sotzny F; Lee CC; Kastner DL; Torrelo A; Zlotogorski A; Moir S; Gadina M; McCoy P; Wesley R; Rother KI; Hildebrand PW; Brogan P; Krüger E; Aksentijevich I; Goldbach-Mansky R
J Clin Invest; 2015 Nov; 125(11):4196-211. PubMed ID: 26524591
[TBL] [Abstract][Full Text] [Related]
14. Patient-Reported Lupus Flare Symptoms Are Associated with Worsened Patient Outcomes and Increased Economic Burden.
Katz P; Nelson WW; Daly RP; Topf L; Connolly-Strong E; Reed ML
J Manag Care Spec Pharm; 2020 Mar; 26(3):275-283. PubMed ID: 32105178
[TBL] [Abstract][Full Text] [Related]
15. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.
Kim H; Brooks KM; Tang CC; Wakim P; Blake M; Brooks SR; Montealegre Sanchez GA; de Jesus AA; Huang Y; Tsai WL; Gadina M; Prakash A; Janes JM; Zhang X; Macias WL; Kumar P; Goldbach-Mansky R
Clin Pharmacol Ther; 2018 Aug; 104(2):364-373. PubMed ID: 29134648
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.
Gómez-Arias PJ; Gómez-García F; Hernández-Parada J; Montilla-López AM; Ruano J; Parra-Peralbo E
Dermatol Ther (Heidelb); 2021 Jun; 11(3):733-750. PubMed ID: 33856640
[TBL] [Abstract][Full Text] [Related]
18. The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA).
Barroso N; Woodworth TG; Furst DE; Guillemin F; Fautrel BJ; Borazan N; Kafaja S; Brook J; Elashoff DA; Ranganath VK
Clin Rheumatol; 2020 Jan; 39(1):189-199. PubMed ID: 31493148
[TBL] [Abstract][Full Text] [Related]
19. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS
N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914
[TBL] [Abstract][Full Text] [Related]
20. Effect of Early and Prophylactic Nonsteroidal Anti-Inflammatory Drugs on Flare Duration in Pediatric Acute-Onset Neuropsychiatric Syndrome: An Observational Study of Patients Followed by an Academic Community-Based Pediatric Acute-Onset Neuropsychiatric Syndrome Clinic.
Brown KD; Farmer C; Freeman GM; Spartz EJ; Farhadian B; Thienemann M; Frankovich J
J Child Adolesc Psychopharmacol; 2017 Sep; 27(7):619-628. PubMed ID: 28696786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
